Ireland's Theravance Biopharma Q4 revenue misses expectations
Overview
Ireland-based respiratory medicines developer's Q4 revenue missed analyst expectations
Company to cut operating expenses by about 60%
Outlook
Theravance expects $60-$70 mln annualized cash flow starting in Q3 2026
Company projects operating expenses to drop about 60% after restructuring
Theravance says Strategic Review Committee is accelerating evaluation of alternatives, including potential sale
Result Drivers
YUPELRI SALES GROWTH - Q4 YUPELRI net sales rose year-over-year, driven by 14% growth in customer demand and 13% higher hospital channel volumes
MILESTONE PAYMENTS - Q4 results benefited from $25 mln YUPELRI and $50 mln TRELEGY sales-based milestone payments
Company press release: ID:nPn26N9d9a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $45.9 mln | $58.50 mln (6 Analysts) |
Q4 EPS |
| $1.15 |
|
Q4 Adjusted Net Income |
| $3.13 mln |
|
Q4 Net Income |
| $61.02 mln |
|
Q4 Operating Income |
| $20.01 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Theravance Biopharma Inc is $15.00, about 8.5% above its March 18 closing price of $13.83
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 21 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
